Applied DNA Reports Fiscal Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Applied DNA Sciences (APDN) Misses Q3 EPS by 5c
August 6, 2020 5:28 PM EDTApplied DNA Sciences (NASDAQ: APDN) reported Q3 EPS of ($0.72), $0.05 worse than the analyst estimate of ($0.67).
We continued during the quarter to position the Company to serve the unmet and evolving needs for COVID-19 testing solutions and vaccine development, said Dr. James A. Hayward, president and CEO of Applied DNA Sciences. Upon the receipt of FDA Emergency Use Authorization (EUA) for our Linea COVID-19 diagnostic assay kit (for use with nasopharyngeal (NP) swab and anterior nasal swab (ANS) sample collections), we put into place the foundation of our COVID-19 diagnostics business: we established the requisite supply... More
